Small-bowel neuroendocrine tumor and retroperitoneal fibrosis: efficacy of octreotide and tamoxifen

Tumori. 2015 Mar 20;101(1):e24-8. doi: 10.5301/tj.5000259.

Abstract

Aims and background: Neuroendocrine tumors are uncommon clinical entities and only a few cases of the co-occurrence of neuroendocrine tumors and retroperitoneal fibrosis have been described in the literature.

Methods and study design: We report the promising results achieved in a case of neuroendocrine tumor complicated by retroperitoneal fibrosis causing right ureteral obstruction treated with long-acting release octreotide and tamoxifen.

Results and conclusions: The treatment resulted in a complete response without toxicity.

Publication types

  • Case Reports

MeSH terms

  • Abdominal Pain / etiology
  • Antineoplastic Agents, Hormonal / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Humans
  • Intestinal Neoplasms / pathology*
  • Intestine, Small*
  • Male
  • Middle Aged
  • Neuroendocrine Tumors / complications*
  • Neuroendocrine Tumors / diagnosis*
  • Neuroendocrine Tumors / drug therapy
  • Neuroendocrine Tumors / pathology
  • Octreotide / administration & dosage
  • Retroperitoneal Fibrosis / complications*
  • Retroperitoneal Fibrosis / diagnosis*
  • Retroperitoneal Fibrosis / drug therapy
  • Retroperitoneal Fibrosis / etiology
  • Tamoxifen / administration & dosage
  • Tomography, X-Ray Computed
  • Treatment Outcome
  • Ureteral Obstruction / etiology*

Substances

  • Antineoplastic Agents, Hormonal
  • Tamoxifen
  • Octreotide